Bifidobacterium breve, probiotic preparations and their application in antidepressant

By using Bifidobacterium brevis, the anxiety and depressive behavior in mice was significantly reduced, the pathological damage to the ileum tissue of the depression model mice was improved, and the inflammatory response was reduced. The problem of high prices and major side effects of existing antidepressants was solved, and a drug was eliminated. Effective methods other than treatment to intervene in depression.

CN118256397B9Active Publication Date: 2024-11-29THANKCOME BIOLOGICAL SCI & TECH CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410676690.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-05-29
Publication Date
2024-11-29
Estimated Expiration
2044-05-29

AI Technical Summary

Technical Problem

Existing antidepressants are expensive, have long treatment time and have side effects, and lack effective prevention and treatment measures. The pathogenesis of depression is complex. The existing probiotics have initial results in the treatment of depression, but more needs to be developed. Strains used to fight depression.

Method used

Provide a Bifidobacter brevis, which is deposited with CGMCC No. 24982, significantly alleviates anxiety and depression behavior in mice, improves ileal histopathological damage in depression model mice, reduces inflammatory response, and stimulates mTOR by activating AKT and ERK signal transduction. Synapse occurs, achieving neuroprotection and neuroplasticity, and improving monoamine neurotransmitter disorders.

Benefits of technology

It significantly alleviated anxiety and depression behavior in mice, improved ileal histopathological damage in depression model mice, reduced proinflammatory cytokine levels, normalized serum 5-HT and ACTH concentrations, and slowed the development of depression through the AKT/mTOR pathway.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118256397B9_ABST
    Figure CN118256397B9_ABST
Patent Text Reader

Abstract

The present invention provides Bifidobacterium breve, microecological preparations and their applications in anti-depression, and relates to the field of microbial technology. The present invention provides a Bifidobacterium breve, which is deposited in the General Microbiological Center of the China Microbiological Culture Collection Administration Committee, and the deposit number is CGMCC No.24982. The Bifidobacterium breve provided by the present invention significantly reduces the anxiety-like and depression-like behaviors of mice; at the same time, it can improve the pathological damage of the ileum tissue of depression model mice, slow down the inflammatory response, and reduce the serum concentrations of pro-inflammatory cytokines IL-6 and TNF-α. In addition, the intervention of Bifidobacterium breve can significantly improve the symptoms of monoamine neurotransmitter disorders in chronic stress mice, which is specifically manifested as the normalization of serum 5-HT and ACTH concentrations. In addition, Bifidobacterium breve can also stimulate mTOR synaptogenesis by activating the signal transduction of AKT and ERK, and slow down the development of depression by achieving neuroprotection, neurogenesis and neuroplasticity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of microorganisms, and in particular relates to Bifidobacterium breve, a microecological preparation and application thereof in anti-depression. Background Art

[0002] Depression is a mental disorder with abnormally low mood or lack of interest and pleasure as the main clinical manifestations. This type of disease has a high prevalence, high recurrence rate, and high disability rate. It can be completely relieved during the intermittent period, and some patients have residual symptoms. Depression seriously affects the patient's life function and physical and mental health, and is the most common mental illness. Therefore, how to prevent, relieve and treat depression is an urgent public issue. Constructing animal models to explore the prevention and treatment of depression is a common and effective means in clinical practice. Among them, the use of chronic unpredictable mild stress (CUMS) modeling produces the best effect, which can better simulate the long-term stress and stimulation suffered by people in daily life. The success or failure of modeling and the effect of intervention can be accurately determined through behavioral science, and it is valued by more and more scientists.

[0003] Depression has an insidious onset, complex and diverse causes, a highly variable course of disease, and inconsistent responses to treatment. A clear pathogenesis has not yet been established. Evidence shows that synaptic plasticity impairment is an important pathogenesis of depression and learning and memory disorders. Brain-derived neurotrophic factor (BDNF) / tyrosine protein kinase (TrkB) is an important regulatory mechanism of synaptic plasticity and neuronal growth, which mediates neuroprotection through the downstream serine / threonine kinase (AKT) / mammalian target of rapamycin (mTOR) signaling pathway. At the same time, the AKT / mTOR signaling pathway can also activate anti-apoptotic pathways to improve depressive behavior. According to the study, the antidepressant drug ketamine can stimulate glutamate transmission, leading to the activation of AKT and ERK signaling, which in turn stimulates mTOR synaptogenesis and increases BDNF and TrkB levels, thereby performing protein transcription, ultimately achieving neuroprotection, neurogenesis, and neuroplasticity. In addition, the mTOR signaling pathway can also play a neuroprotective role by regulating autophagy, promoting protein synthesis, and inducing neural regeneration. mTOR can participate in the formation of two different forms of protein complexes, namely mTORC1 and mTORC2. mTORC1 is crucial in various physiological processes related to the central nervous system. It is mainly responsible for regulating neuronal development, neurogenesis, and synaptic plasticity, while mTORC2 promotes cell survival and cytoskeletal organization. In addition, peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), as a transcriptional coregulator, regulates mitochondrial biogenesis and enhances oxidative phosphorylation, which can promote the disposal of neurotoxic metabolites such as kynurenine to effectively prevent stress-induced depression. The neurotransmitter 5-hydroxytryptamine (5-HT; also known as serotonin) is involved in regulating functions such as mood, memory, cognition, appetite, and sleep. Its normal expression in the body can effectively prevent the occurrence of depression. Therefore, targeting factors related to the AKT / mTOR pathway is of great significance for intervening in the development of depression.

[0004] At present, there is no perfect prevention and treatment measure for depression. Common antidepressants are expensive, take a long time to treat, have unsatisfactory effects, and have certain side effects when taken for a long time. Therefore, it is particularly urgent to find methods other than drug therapy to intervene in the development of depression. Preclinical and clinical trials have shown that intestinal microorganisms play an important role in the gut-brain axis and are related to the pathological mechanisms of various neuropsychiatric disorders such as stress, autism, depression and dementia. As beneficial microorganisms, probiotics have a wide range of physiological effects on promoting host health. They can maintain a healthy intestinal environment by balancing the intestinal microbiota, ensure the normal operation of the gut-brain axis, and have an auxiliary therapeutic effect on neuropsychiatric disorders. At the same time, more and more clinical evidence shows that probiotics can regulate stress responses and improve mood and anxiety symptoms in patients with chronic fatigue and irritable bowel syndrome. Among them, Lactobacillus paracasei PS23 can reverse anxiety and depression-related behaviors caused by long-term corticosterone exposure. Lactobacillus fermentum PS150 has been shown to reverse the decline in serotonin levels in the brains of rats exposed to chronic mild stress, reduce the plasma concentration of corticosterone, and restore normal behavior in rats. In rats, Lactobacillus helveticus NS8 improved behavioral and cognitive impairments induced by chronic stress, reduced plasma concentrations of corticosterone (CORT) and adrenocorticotropic hormone (ACTH), restored hippocampal levels of 5-HT and norepinephrine, and increased hippocampal expression of the gene encoding brain-derived neurotrophic factor (BDNF). Bifidobacterium breve CCFM1025 can alleviate major depressive disorder by regulating the gut microbiome and tryptophan metabolism.

[0005] Research on the use of probiotics in the treatment of depression has shown initial results, but more probiotics need to be developed for anti-depression purposes. Summary of the invention

[0006] In order to solve the above problems, the present invention provides the application of Bifidobacterium breve in anti-depression. The present invention provides a Bifidobacterium breve, which is deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration Committee, and the deposit number is CGMCC No. 24982. The Bifidobacterium breve provided by the present invention significantly reduces the anxiety-like and depression-like behaviors of mice; at the same time, it can improve the pathological damage of the ileum tissue of depression model mice, slow down the inflammatory response, and reduce the serum concentrations of proinflammatory cytokines IL-6 and TNF-α. In addition, the intervention of Bifidobacterium breve can significantly improve the symptoms of monoamine neurotransmitter disorders in chronic stress mice, which is specifically manifested as the normalization of serum 5-HT and ACTH concentrations. In addition, Bifidobacterium breve can also stimulate mTOR synaptogenesis by activating the signal transduction of AKT and ERK, and slow down the development of depression by achieving neuroprotection, neurogenesis and neuroplasticity.

[0007] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0008] On the one hand, the present invention provides a Bifidobacterium breve, which has been deposited in the General Microbiological Center of China National Microbiological Culture Collection Administration on May 30, 2022, with the deposit number of CGMCC No. 24982.

[0009] On the other hand, the present invention provides a probiotic preparation, which comprises one or more of a culture, a culture extract, a bacterial cell, a fermentation broth, a fermentation broth precipitate, and a freeze-dried powder of Bifidobacterium breve, and the preservation number of the Bifidobacterium breve is CGMCC No. 24982.

[0010] In another aspect, the present invention provides the use of Bifidobacterium breve or its microecological preparation in the preparation of medicines, health products or foods; the preservation number of the Bifidobacterium breve is CGMCC No. 24982.

[0011] Specifically, the microecological preparation comprises one or more of the culture, culture extract, bacteria, fermentation broth, fermentation broth precipitate, and freeze-dried powder of Bifidobacterium breve.

[0012] Specifically, the medicine is used to prevent and treat mental illness, or the medicine is used for sedation or hypnosis.

[0013] More specifically, the mental illness includes depression, anxiety, and convulsions.

[0014] Preferably, the mental illness is depression.

[0015] More specifically, the medicine also includes other pharmaceutically acceptable excipients.

[0016] Preferably, the pharmaceutically acceptable excipients include, but are not limited to, solvents, diluents, disintegrants, precipitation inhibitors, surfactants, glidants, adhesives, lubricants, dispersants, suspending agents, isotonic agents, thickeners, emulsifiers, preservatives, stabilizers, hydrating agents, emulsification accelerators, buffers, absorbents, colorants, flavoring agents, sweeteners, ion exchangers, release agents, coating agents, flavoring agents or antioxidants.

[0017] More specifically, the dosage form of the drug includes, but is not limited to, enteral dosage form and parenteral dosage form according to the administration method.

[0018] Preferably, the dosage forms for administration via the gastrointestinal tract include, but are not limited to, tablets, powders, granules, solutions, capsules, emulsions, suspensions, and oils.

[0019] Preferably, the gastrointestinal administration dosage form includes but is not limited to an injection dosage form, a respiratory tract administration dosage form, a skin administration dosage form, a mucosal administration dosage form and a cavity administration dosage form.

[0020] Specifically, the food includes but is not limited to candy flakes, soy milk, yogurt, canned food, biscuits, chocolate, cakes, cream, cheese, milk powder, ice cream, popsicles, jam, puree, candied fruit, preserved fruit, bread, egg rolls, protein drinks, solid drinks, lactic acid bacteria drinks, plant protein drinks, carbonated drinks, coffee, puffed foods or health foods.

[0021] Preferably, the health food comprises tea products, granules, medicinal wine, capsules, fruit juice, fruit vinegar, granules, fermented milk products, fermented cereal products, fermented bean products, powders, honey pastes or meal replacement powders.

[0022] Further preferably, the health food further comprises conventional supplementary materials for health food, and the conventional supplementary materials for health food include but are not limited to fillers, flavoring agents, binders, disintegrants, lubricants, antacids or nutritional enhancers.

[0023] Specifically, the health care product has the effects of assisting in improving memory and improving sleep.

[0024] More preferably, the health food comprises an emulsion product, a solution product, a powder product or a solid product.

[0025] Specifically, the medicine, health product or food contains 1×10 7 CFU / g-1×10 9 CFU / g of Bifidobacterium breve.

[0026] Specifically, the medicine, health product or food contains 1×10 7 CFU / g or 1×109 CFU / g of Bifidobacterium breve.

[0027] Specifically, the Bifidobacterium breve improves 5-HT and ACTH levels, downregulates inflammatory factor levels, activates AKT and ERK signal transduction, and stimulates mTOR synapse formation, thereby protecting nerves.

[0028] In another aspect, the present invention provides a medicine comprising Bifidobacterium breve or its microecological preparation, wherein the preservation number of the Bifidobacterium breve is CGMCC No. 24982.

[0029] In another aspect, the present invention provides a health product comprising Bifidobacterium breve or a microecological preparation thereof, wherein the preservation number of the Bifidobacterium breve is CGMCC No. 24982.

[0030] In another aspect, the present invention provides a food comprising Bifidobacterium breve or its probiotic preparation, wherein the preservation number of the Bifidobacterium breve is CGMCC No. 24982.

[0031] The beneficial effects of the present invention are:

[0032] (1) The present invention provides a Bifidobacterium breve, which is deposited in the General Microbiological Center of China National Microbiological Culture Collection Administration with a deposit number of CGMCC No. 24982.

[0033] (2) The oral administration of Bifidobacterium breve provided by the present invention can significantly reduce the anxiety-like and depression-like behaviors of mice in the open field test, tail suspension test and forced swimming test; at the same time, it can improve the pathological damage of the ileum tissue of the depression model mice, alleviate the inflammatory response, and reduce the serum concentrations of the proinflammatory cytokines IL-6 and TNF-α.

[0034] (3) The intervention of Bifidobacterium breve provided by the present invention can significantly improve the symptoms of monoamine neurotransmitter imbalance in chronic stressed mice, specifically manifested by the normalization of serum 5-HT and ACTH concentrations.

[0035] (4) The Bifidobacterium breve provided by the present invention can also activate the signal transduction of AKT and ERK, stimulate mTOR synaptogenesis, and slow down the development of depression by achieving neuroprotection, neurogenesis and neuroplasticity.

[0037] Biomaterial: BB05;

[0038] Classification name: Bifidobacterium breve Bifidobacterium breve ;

[0039] Deposit number: CGMCC No. 24982;

[0040] Deposit date: May 30, 2022;

[0041] Depository: General Microbiology Center, China Microbiological Culture Collection Administration;

[0042] Abbreviation of depository unit: CGMCC;

[0043] Collection address: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] Figure 1 The weight changes of mice in each group; different lowercase letters indicate statistically significant differences as tested by Duncan's multiple range test (p < 0.05).

[0045] Figure 2 The results of the open field test; different lowercase letters indicate statistically significant differences as determined by Duncan's multi-range test (p < 0.05).

[0046] Figure 3 This is an open field action trajectory diagram.

[0047] Figure 4 The effects of tail suspension and forced swimming behavior on mice; A is the immobility time of tail suspension; B is the number of immobility times of tail suspension; C is the proportion of immobility time of tail suspension; D is the proportion of immobility time of forced swimming; different lowercase letters indicate that the differences are statistically significant (p < 0.05) after Duncan's multi-range test.

[0048] Figure 5 These are histopathological images of mouse ileum.

[0049] Figure 6 The results of determination of serum 5-HT, ACTH, IL-6 and TNF-α in mice; A is the serum 5-HT concentration; B is the serum ACTH concentration; C is the serum IL-6 concentration; D is the serum TNF-α; different lowercase letters indicate that the differences are statistically significant by Duncan multi-range test (p < 0.05).

[0050] Figure 7 is the expression level of mTOR pathway-related genes in the prefrontal cortex of the mouse brain; A is mTOR Relative expression level; B is mTORC1 Relative expression level; C is mTORC2 Relative expression level; D is AKT Relative expression level; E is ERK Relative expression level; F is PGC-1α Relative expression level; different lowercase letters indicate statistically significant differences as measured by Duncan's multivariate test (p < 0.05). DETAILED DESCRIPTION

[0051] In order to make the technical means, creative features, purpose and efficacy of the present invention easy to understand, the present invention is further explained in conjunction with specific embodiments below, but the following embodiments are only preferred embodiments of the present invention, not all. Based on the embodiments in the implementation mode, other embodiments obtained by those skilled in the art without creative work all belong to the protection scope of the present invention. In the following embodiments, unless otherwise specified, the operating methods used are conventional operating methods, the equipment used are conventional equipment, and the equipment materials used in each embodiment are the same.

[0052] 1. The experimental reagents used in the present invention are shown in Table 1:

[0053] Table 1 Experimental reagents

[0054]

[0055] 2. The experimental instruments used in the present invention are shown in Table 2:

[0056] Table 2 Experimental instruments

[0057]

[0058] 3. Experimental strains

[0059] The strain used in the present invention is Bifidobacterium breve, which is separated from breast milk of healthy adults in Zhangpu Town, Kunshan City, Jiangsu Province, and is preserved in the General Microbiological Center (CGMCC) of China Microbiological Culture Collection Committee with the preservation number of CGMCC No. 24982.

[0060] 4. Experimental Animals

[0061] The present invention selected 50 6-week-old SPF-grade male C57BL / 6 mice, purchased from Hunan Slake Jingda Experimental Animal Co., Ltd., license number: SCXK (Xiang) 2019-0004. They were kept in the barrier system animal room of the Collaborative Innovation Center for Children's Nutrition and Healthy Development, with an ambient temperature of 25 ± 2°C, a humidity of 50 ± 5%, light and dark alternation every 12 h, and free access to food and water. This animal experiment was approved by the Collaborative Innovation Center for Children's Nutrition and Healthy Development.

[0062] 5. Statistical analysis

[0063] All numerical values ​​in the experiment are expressed as (mean ± standard deviation). The results were tested for homogeneity of variance using one-way ANOVA in SPSS software. Different letters in the charts indicate significant differences after Duncan multi-scale test ( p <0.05).

[0064] Example 1 Animal Experiment Design

[0065] The present invention constructs a CUMS depression mouse model, selects fluoxetine as a positive drug control, and evaluates the intervention effect of Bifidobacterium breve in depression model mice. The animal experiment is designed as follows:

[0066] After 1 week of adaptive feeding, the mice were randomly divided into a normal group, a model group, a fluoxetine group (drug positive control), a low-concentration Bifidobacterium breve group, and a high-concentration Bifidobacterium breve group, with 10 mice in each group. The experimental period was seven weeks. During the experiment, the experimental mice were gavaged or intraperitoneally injected once a day at a fixed time period. The specific treatment methods are shown in Table 1 below. Except for the normal group, mice in each group were subjected to chronic unpredictable mild stimulation (CUMS) for 5 weeks. The treatment methods are shown in Table 3 below. Behavioral tests began in the 6th week, including open field test, tail suspension test, and forced swimming test. All mice were euthanized and samples were collected in the 7th week.

[0067] Table 3 Animal experimental groups and treatment methods

[0068]

[0069] Construction of CUMS experimental animal model:

[0070] According to the CUMS depression modeling method, the first to fifth weeks of the experiment were the modeling period. Mice were subjected to 10 different stimuli, with one stimulus randomly given every day. The same stimulus could not be applied for three consecutive days to ensure that the animals could not expect: (1) Slanted cage: lift one end of the cage and tilt it 45° for 24 hours; (2) Fasting: remove the mouse food for 24 hours; (3) Water deprivation + empty bottle stimulation: pour out the water in the water bottle and put it back in place for 24 hours; (4) No bedding: take out the bedding for 8 hours; (5) Continuous light for 24 hours; (6) Crowded stimulation: place partitions in the mouse cage to reduce the activity area of ​​the mice for 24 hours; (7) Tail clamping: clamp the tail 1 cm away from the tip with hemostatic forceps for 60 seconds; (8) Day and night reversal: adjust the day and night cycle, cover the mouse cage with black cloth during the day, remove the black cloth at night, turn on the light, and create a dark day and bright night environment; (9) Restraint: limit the mouse cage to 50 mL plastic syringe, 2 h; (10) Wet bedding: 200 mL of water is sprinkled on the bedding, 8 h. The success of the model is analyzed and judged based on the subsequent comparison of mouse physical signs and the results of behavioral experiments. Normal mice have smooth and shiny fur and are in good spirits, while depressed mice have yellow and dull fur, are listless, and have significantly reduced cleanliness.

[0071] Example 2 Effect of Bifidobacterium breve on body weight changes in mice

[0072] During the animal experiment, the body weight of each group of mice was recorded weekly. Figure 1There was no significant difference in the weight of mice in each group before the formal experiment. The weight growth trend of mice was basically the same in the first two weeks of CUMS modeling. After two weeks of induction, compared with the normal group, the weight growth rate of mice in the model group, fluoxetine group, low-concentration Bifidobacterium breve group and high-concentration Bifidobacterium breve group decreased, and the weight of each group began to show significant differences ( p <0.05). Starting from the third week, the body weight of mice in the model group decreased significantly ( p <0.05). At the end of the 6th week of experimental modeling, the model group had the lightest body weight, and the other four groups had significant differences ( p <0.05), among which the weight of the high-concentration Bifidobacterium breve group was significantly heavier than that of the low-concentration Bifidobacterium breve group and the fluoxetine group. The results showed that the weight gain rate of mice decreased after CUMS induction, while the weight gain rate of mice increased after intervention with fluoxetine and Bifidobacterium breve. The high-concentration Bifidobacterium breve group showed an effective effect in maintaining the normal weight of mice, and its effect was better than that of the low-concentration Bifidobacterium breve group and the fluoxetine group.

[0073] Example 3 Behavioral Experiment

[0074] In rodent depression model-related research, behavioral testing of animals can predict the progress of modeling and truly reflect the depressive state of animals through animal behavior before conducting molecular and cellular studies. The behavioral testing method refers to the method described by Tian Peijun et al.

[0075] Open field experiment: The open field is a cuboid of 50 cm × 50 cm × 50 cm (length × width × height). At the beginning of the experiment, the mouse should be placed in the center of the open field, and the timer should be started immediately and the whole process should be recorded. The observation time is 6 min, and silence should be maintained during the experiment. After each experiment, the open field should be cleaned, feces should be picked up, and disinfected with medical alcohol to eliminate the odor left by the previous mouse. ANY maze 7.0 software was used to perform digital analysis on the mouse behavior video, recording the total distance the mouse moved in the open field, the number of times it entered the central area, and the time it spent in the central area.

[0076] Tail suspension test: The mouse tail was fixed to a stand with tape at about 1.5 cm from the end, so that it remained suspended in the air with its head facing downward and about 30 cm from the ground. The video was recorded for 6 min, and the immobility time from 3 to 6 min after tail suspension was analyzed using AYN-mase 7.0 software (judgment criteria: 2 s, 82%, i.e., the mouse was judged to be in an immobile state if the repetition rate of the mouse outline reached 82% within 2 s).

[0077] Forced swimming test: used to evaluate the depressive-like behavioral characteristics of rodents. Each mouse swam alone in a transparent cylindrical glass tank (12 cm in diameter, about 30 cm deep) filled with clean water, and the water temperature was maintained at 23-25°C. One day before the experiment, all mice were given 10 min of adaptive training. In the formal experiment, each mouse swam for 6 min. The immobility time (immobility, the judgment standard is that the limbs are immobile or only the hind limbs move slightly) of each mouse was observed and recorded. After swimming, quickly wipe with a towel and blow dry with hot air to prevent the mouse from catching a cold.

[0078] Taking advantage of the conflicting psychology formed by rodents' exploratory nature towards novel environments and their aversion to bright light and open areas, an open field test is used to evaluate their anxiety-like behavior. The shorter the time spent in the central area, the more serious the problem.

[0079] like Figure 2-Figure 3 As shown, the total distance traveled by mice in the model group in the open field was 6.52 ± 2.38 m, which was significantly lower than that in other groups ( p <0.05). At the same time, the number of intermediate grid crossings of mice in the normal group, fluoxetine group, and Bifidobacterium breve group was significantly higher than that of the model group (1.83 ± 0.41 times ( p <0.05, and the high concentration of Bifidobacterium breve group was higher than the low concentration of Bifidobacterium breve group. In addition, the mice in the model group had the lowest percentage of time spent in the middle compartment (5 ± 1.75%), which was significantly different from the other four groups ( p <0.05), after intervention with fluoxetine and Bifidobacterium breve, the percentage of mice staying in the middle compartment increased significantly. The results showed that CUMS induced anxiety in mice and greatly reduced their activity level, which was significantly improved after intervention with fluoxetine and Bifidobacterium breve, and the activity level of mice tended to be normal, and the regulatory effect of high concentration of Bifidobacterium breve was better than that of low concentration of Bifidobacterium breve.

[0080] The tail suspension test and forced swimming test reflect the despair of animals, and the immobility time is positively correlated with their despair. Figure 4 As shown in A, the tail suspension time of mice in the normal group was 134.42 ± 13.56 s, which was significantly higher in the model group (211.72 ± 3.49 s), indicating that the mice in the model group had strong despair and gave up struggling. After intervention with fluoxetine and Bifidobacterium breve, the tail suspension time of mice was significantly lower than that of the model group ( p <0.05), especially in the high-concentration group of Bifidobacterium breve, the tail suspension immobility time of mice was not significantly different from that in the fluoxetine group ( p >0.05). At the same time, the trends of the number of tail suspension immobility and the percentage of tail suspension immobility time were consistent with the tail suspension immobility time of mice. Figure 4D in the figure shows that the proportion of immobility time in forced swimming in the model group was significantly higher than that in the normal group, fluoxetine group and high-concentration Bifidobacterium breve group. This further illustrates the strong despair of the mice in the model group, and the intervention of fluoxetine and Bifidobacterium breve can effectively improve this situation, and the effect of the high-concentration Bifidobacterium breve group is better than that of the low-concentration Bifidobacterium breve group.

[0081] Example 4: Dissection and sample collection

[0082] Fasting but not drinking water was allowed for 12 h before the dissection. The whole blood of the mice was collected and allowed to stand at room temperature for 30 min. The blood was centrifuged at 4000 r / min for 15 min at 4°C. The upper serum was aspirated and stored at −80°C after appropriate aliquoting. The hippocampus and prefrontal cortex were carefully dissected out on ice, placed in sterile centrifuge tubes, and stored at −80°C for use. At the same time, 0.5 cm of clean ileum without feces was taken and placed in a centrifuge tube containing 1.5 mL of tissue fixative.

[0083] 4.1 Observation of ileum pathological damage

[0084] The ileum tissue was sliced, then dewaxed, and soaked in ethanol to hydrate the slices. After washing with distilled water, the slices were stained with hematoxylin staining solution for 20 minutes, and then rinsed under tap water until the slices turned blue. The next step was to place the slices in a 1% hydrochloric acid ethanol solution, let it stand for 10 seconds, then take it out and rinse it with tap water. The slices were then stained with eosin for 2 minutes, dehydrated with high-concentration alcohol, and then soaked in xylene. Finally, they were sealed with coverslips and the pathological changes of the tissues were observed under an optical microscope.

[0085] like Figure 5 As shown in the figure, the ileum cells of the mice in the normal group were arranged neatly and orderly, with complete structure, clear layers, no damage, no inflammation, no swelling, and were in a healthy state. The ileum cells of the model group were arranged in a disorderly manner, the crypt structure was abnormal, a large number of inflammatory cells were seen to gather, the mucosal layer showed a certain degree of swelling, and symptoms of local mucosal shedding appeared. Compared with the model group, the intervention of fluoxetine and Bifidobacterium breve had a significant improvement effect on intestinal damage. It can be seen that the intestinal structure was intact, the crypt structure was healthy, the villi were neat, and the goblet cells were abundant. Overall, no serious adverse pathological changes were observed in the ileum of mice. Only local inflammatory cell infiltration was observed in the intestine of mice in the low-concentration group of Bifidobacterium breve. Our results show that Bifidobacterium breve intervention can significantly improve the pathological damage of mouse ileum tissue caused by chronic stress stimulation, and the effect of the high-concentration group is better than that of the low-concentration group.

[0086] 4.2 ELISA for the determination of serum related factor expression

[0087] The expression levels of 5-HT, ACTH, IL-6 and TNF-α in mouse serum were determined by enzyme-linked immunosorbent assay. The experiment was carried out strictly according to the steps in the manufacturer's operating instructions of the ELISA kit.

[0088] As a neurotransmitter, 5-HT can guide the brain to produce pleasant emotions. The reduction of 5-HT is directly related to psychological and emotional changes, which in turn induces the occurrence of depression. That is, the higher the 5-HT concentration, the lower the degree of depression. Figure 6 As shown in A, the 5-HT level of mice in the model group was the lowest. After intervention with fluoxetine and Bifidobacterium breve, the serum 5-HT concentration of mice increased to a certain extent, among which the high-concentration group of Bifidobacterium breve was higher than that of the fluoxetine group and the low-concentration group of Bifidobacterium breve. At the same time, CUMS can lead to a significant increase in the serum adrenocorticotropic hormone (ACTH) of mice ( Figure 6 B in the study), while intervention with fluoxetine and high concentrations of Bifidobacterium breve can reduce the increase in ACTH caused by CUMS. In addition, IL-6 and TNF-α are key proinflammatory cytokines that play an important role in the regulation of inflammation and immunity. Figure 6 C and Figure 6 It can be seen from D in that the levels of IL-6 and TNF-α in the serum of mice in the model group were the highest among all groups, indicating that chronic stress stimulation can lead to increased levels of inflammation in mice. After intervention with fluoxetine and Bifidobacterium breve, the concentrations of proinflammatory cytokines IL-6 and TNF-α in the serum of mice were significantly reduced ( p <0.05), indicating that both fluoxetine and Bifidobacterium breve had a good effect in alleviating inflammation in mice, among which high concentration of Bifidobacterium breve had a better effect than low concentration.

[0089] 4.3 RT-qPCR determination of mRNA expression of related genes in hippocampus and prefrontal cortex

[0090] Real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) is a method that uses fluorescent chemicals to measure the total amount of products after each polymerization chain reaction cycle in a DNA amplification reaction, and quantitatively analyzes specific DNA sequences in the sample to be tested through internal or external reference methods. The specific methods are as follows:

[0091] (1) Extract total RNA from tissues.

[0092] (2) Determine RNA concentration and purity: Dilute the RNA stock solution and use a micro-spectrophotometer to determine the RNA concentration and purity. An A260 / A280 ratio between 1.8 and 2.0 indicates good RNA purity.

[0093] (3) Reverse transcription: Follow the instructions of the synthesis kit to reverse transcribe RNA into cDNA.

[0094] (4) qPCR amplification: pre-denaturation at 95°C for 5 min, one cycle; denaturation at 95°C for 10 sec, annealing / extension at 60°C for 30 sec, 40 cycles.

[0095] (5) Taking HPrT as the internal reference, according to Formula 2 −ΔΔCT Calculate the relative mRNA expression of each target gene. Table 4 shows the primer sequences used in this experiment.

[0096] Table 4 Primer sequences

[0097]

[0098] Note: In the table, "F" represents the upstream primer and "R" represents the downstream primer.

[0099] like Figure 7 As shown, chronic stress leads to changes in the prefrontal cortex of mice AKT / mTOR pathway-related factors were lowly expressed in the model group compared with the normal group. mTOR, mTORC1, mTORC2, AKT, ERK and PGC-1α The expression level of p < 0.05), while after intervention with fluoxetine and Bifidobacterium breve, the prefrontal cortex of mice mTOR, mTORC1, mTORC2, AKT, ERK and PGC-1α The expression level of p < 0.05), among which the mice in the high concentration group of Bifidobacterium breve mTOR, mTORC1, mTORC2 The expression levels of ERK and PD-1 in the rats were even higher than those in the drug treatment group (fluoxetine). AKT / It has a significant effect on normalizing the expression levels of mTOR pathway-related factors, and the effect of the high-concentration Bifidobacterium breve group is significantly better than that of the low-concentration group.

[0100] In summary, the research of the present invention shows that the concentration of 1.0 × 10 9 CFU / kg of Bifidobacterium breve gavage intervention can significantly reduce the anxiety-like and depression-like behaviors of mice in the open field test, tail suspension test and forced swimming test; at the same time, it can improve the pathological damage of the ileum tissue of depression model mice, slow down the inflammatory response, and reduce the serum concentrations of proinflammatory cytokines IL-6 and TNF-α; in addition, the intervention of Bifidobacterium breve can significantly improve the symptoms of monoamine neurotransmitter disorders in chronic stressed mice, specifically manifested by the normalization of serum 5-HT and ACTH concentrations. In addition, Bifidobacterium breve can also activate AKT and ERK signal transduction, stimulation mTOR Synaptogenesis, slowing the development of depression by achieving neuroprotection, neurogenesis, and neuroplasticity.

[0101] Therefore, the present invention shows the significant effect of Bifidobacterium breve in improving the depressive-like behavior of CUMS mice, reveals the specific mechanism by which Bifidobacterium breve improves the depressive-like behavior of mice based on AKT / mTOR pathway-related genes, and provides a scientific basis for the intervention effect of Bifidobacterium breve on depression.

[0102] The above detailed description is a specific description of one of the feasible embodiments of the present invention, and the embodiment is not intended to limit the scope of the present invention. It should be pointed out that any equivalent implementation or change that does not deviate from the present invention should be included in the scope of the technical solution of the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the attached requirements.

Claims

1. Bifidobacterium breve ( Bifidobacterium breve ) or its microecological preparation in the preparation of medicines for preventing and treating mental illness, characterized in that, The preservation number of the Bifidobacterium breve is CGMCC No. 24982, and the mental illness is depression or anxiety.

2. The use according to claim 1, characterized in that: The microecological preparation comprises one or more of the following: cells of Bifidobacterium breve, fermentation liquid, fermentation liquid precipitation and freeze-dried powder.

3. The use according to claim 1, characterized in that: The drug contains 1×10 7 CFU / g-1×10 9 CFU / g of Bifidobacterium breve.

4. The use according to claim 3, characterized in that: The drug contains 1×10 7 CFU / g or 1×10 9 CFU / g of Bifidobacterium breve.

5. A medicine comprising Bifidobacterium breve or its microecological preparation, wherein the preservation number of the Bifidobacterium breve is CGMCC No. 24982.

Citation Information

Patent Citations

  • Bifidobacterium breve CCFM1025, fermented food and application thereof

    CN108949640A

  • Bifidobacterium breve preparation with function of relieving depression and anxiety

    CN116637142A